Group items tagged

Crigler-Najjar syndrome arises due to the lack or deficiency of the enzyme uridine diphosphate glucuronosyl transferase. Type 1 and type 2 forms of the disease have been described.

GSK has received approval from FDA for its Tanzeum subcutaneous injection to improve glycemic control, along with diet and exercise, in adult patients with type 2 diabetes.

Scottish biotechnology firm TC BioPharm (TCB) and Japanese immuno-cell therapy company Medinet have entered into a strategic collaboration to develop a new treatment for different types of cancer.

PBR Staff Writer Published 01 May 2014 The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) Incruse Ellipta (umeclidinium) for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic.

PBR Staff Writer Published 27 March 2014 The European Commission (EC) has granted marketing authorization for GlaxoSmithKline's (GSK's) once-weekly diabetes treatment, Eperzan (albiglutide). The drug is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control as monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance.

Liver cancer surgery involves removing the cancerous tissue from the liver, and it can be done in several ways, depending on the stage of the cancer and the patient's overall health.